IDEXX Laboratories IDXX

Name: IDXX Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored March 14, 2026

Price at analysis: $575.72

Crucible Score

58.9

C+

Quality × Value Composite

KQI — Quality

77.9

B+

Fundamental Quality Index

KVI — Value

35.7

D-

Valuation Attractiveness Index

Crucible Verdict — IDXX

IDEXX Laboratories delivers strong quality fundamentals with an 84 Financial Quality score and consistent 89% earnings beat rate, but trades at a significant premium with a 35.7 value score. IDXX's veterinary diagnostics moat remains durable, yet insider selling amid modest overvaluation suggests limited upside until growth accelerates or multiples compress.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality

83.5

Growth Profile

75.0

Moat Durability

80.4

Management Effectiveness

75.3

Diversification & Resilience⚠

54.0

Market Position

80.0

Weakest dimension: Diversification & Resilience (54.0)

◆ KVI Value Dimensions

DCF Margin of Safety

38.6

FCF Yield & Cash Returns

32.5

Relative Valuation

22.5

Growth-Adjusted Value

31.9

Historical Valuation

78.7

Macro Context

5.0

◆ DCF Valuation Scenarios

Bear Case

$382.50

Base Case

$555.80

Bull Case

$795.40

Price at Analysis

$575.72

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$382.50	6.0%	29.0%	13.8%
🟢 Base	$555.80	8.0%	32.0%	13.3%
🟢 Bull	$795.40	10.0%	35.0%	12.8%

Key Assumptions: WACC calculated using CAPM with 4.39% risk-free rate, 1.70 beta, and 5.5% ERP yielding ~13.7% base cost of equity; debt is modest so WACC approximates cost of equity at 13.0-13.8%. Revenue growth anchored to 5-year historical CAGR of ~7.5% with operating margins ranging from 29-35% across scenarios reflecting historical 27-32% range with modest expansion potential. Capex intensity held at ~3% of revenue consistent with historical average, and FCF conversion remains strong given asset-light diagnostics model.

◆ Financial Snapshot

Profitability

Gross Margin61.8%

Operating Margin31.6%

Net Margin24.6%

ROIC39.0%

ROE-392.3%

Balance Sheet

Balance SheetCR: 1.17

Cash ConversionFCF/EPS: 0.99x

Capital IntensityCapex/Rev: 2.9%

Altman Z-Score21.02 (Safe)

Piotroski F-Score7/9 (Good)

Growth

Revenue CAGR7.6% CAGR

Earnings CAGR9.2% CAGR

Growth ConsistencyCV: 0.37

Segment Breadth2/2 growing (100%)

Quarterly TrendRev↑, Margin↑, Exp↓

Earnings CredibilityConsistent Beater

◆ Analyst Consensus & Leadership

Leadership & Governance

CEOJon Lichen · 6 years

CEO Ownership< 1%

Compensation81% performance-based

Insider ActivitySelling

Capital AllocationROIC 39.0% vs WACC 2.8%

Earnings Beat Rate89% (18/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted March 14, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.